All posts by: Michael Zand

About Michael Zand

Growth Insights on the Global CRISPR/Cas9 Tools Market 2017: A Disruptive Technology – Gene-editing Tools for … – Business Wire (press release)

Continue reading

2017-12-12 NEWS

Growth Insights on the Global CRISPR/Cas9 Tools Market 2017: A Disruptive Technology – Gene-editing Tools for …
Business Wire (press release)
Since its inception, CRISPR has gained strong traction from the global research community because of its huge potential in diverse applications. Considering CRISPR’s disruptive and game-changing applications, a number of large and small participants
Vertex Pharma (VRTX) CRISPR Therapeutics (CRSP) to Co-Develop and Co-Commercialize CTX001 as CRISPRStreetInsider.com
Crispr Therapeutics (CRSP) Rating Reiterated by CannThe Lincolnian Online
Crispr Therapeutics (CRSP) Earning Somewhat Positive News Coverage, Report ShowsWeek Herald

all 6 news articles »

Continue reading

2017-12-12 NEWS

Business Insider

Paralysed rats walk again after breakthrough surgery using stem cells from a human’s mouth
Business Insider
Seeing a rat scurry by would send many people running away screaming, but researchers at Israel’s Technion institute of technology were joyful when they saw one particular rodent walking. The rat, once paralysed with a completely severed spinal cord

and more »

Continue reading

2017-12-12 NEWS

Sanvada Tech News (blog)

Biotech Companies Are Preparing the First CRISPR Test on Humans
Sanvada Tech News (blog)
This technology for gene-editing treatment has been in the works for quite some time, but could finally come to market due to a company known as CRISPR Therapeutics. The company says it’s ready to test its findings on people, and as such, it has asked

Continue reading

2017-12-12 NEWS

Vertex Pharma (VRTX) CRISPR Therapeutics (CRSP) to Co-Develop and Co-Commercialize CTX001 as CRISPR
StreetInsider.com
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) and CRISPR Therapeutics AG (NASDAQ: CRSP) today announced that the companies will co-develop and co-commercialize CTX001, an investigational gene editing treatment, as part of the companies’ previously
Crispr Therapeutics (CRSP) Rating Reiterated by CannThe Lincolnian Online

all 3 news articles »

Continue reading

2017-12-12 NEWS

Genetic Literacy Project

Gene therapy challenge: How much should it cost and how do we …
Genetic Literacy Project
When evaluating the high prices of one-time gene therapy treatments, should we look to the costs of organ transplants when deciding what’s appropriate?

and more »